Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107886 · ClinicalTrials.gov registry record · Phase 4
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 18,206
- Enrollment target
NCT01107886 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 18,206 participants.
The verdict
NCT01107886, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18,206 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
Interventions
- DRUG Placebo
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,206 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107886
The ClinicalTrials.gov registry entry for NCT01107886 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18,206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01107886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01107886 about?
NCT01107886 is a clinical study titled "Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications". The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
What is the current status of trial NCT01107886?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18,206 participants. The study started on 2010-05. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01107886?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT01107886?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.